Results 91 to 100 of about 260,112 (235)

Tuberculosis in Sudan: A Comprehensive Narrative Review of Epidemiological Trends, Diagnosis, Drug Resistance, Challenges, and Data Gaps

open access: yesHealth Science Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background and Aims This narrative review aims to provide a comprehensive overview of tuberculosis (TB) in Sudan, focusing on prevalence, drug resistance patterns, and associated challenges while identifying knowledge gaps in scientific research and data needed for effective management.
Mohammad Azhar Kamal   +3 more
wiley   +1 more source

MDR-TB electronic medical records abstraction tool.

open access: yes
MDR-TB electronic medical records abstraction tool.
J. Christo Heunis (13046945)   +3 more
core   +1 more source

Epidemic Levels of Drug Resistant Tuberculosis (MDR and XDR-TB) in a High HIV Prevalence Setting in Khayelitsha, South Africa. [PDF]

open access: yes, 2010
BACKGROUND: Although multidrug-resistant tuberculosis (MDR-TB) is emerging as a significant threat to tuberculosis control in high HIV prevalence countries such as South Africa, limited data is available on the burden of drug resistant tuberculosis and ...
McDermid, Cheryl   +41 more
core   +2 more sources

Bioengineered Extracellular Vesicles Mitigate Neuroinflammation by Neutralizing Pneumolysin and Delaying Disease Onset in Experimental Pneumococcal Meningitis

open access: yesJournal of Extracellular Vesicles, Volume 15, Issue 9, September 2026.
ABSTRACT Bacterial meningitis is a life‐threatening neurological disorder frequently caused by a Streptococcus pneumoniae (the pneumococcus) infection of the brain. Standard treatment consists of antibiotics to eliminate bacteria and dexamethasone to reduce inflammation.
Kristine Farmen   +9 more
wiley   +1 more source

CTSs’ knowledge about MDR-TB.

open access: yes, 2022
CTSs’ knowledge about MDR-TB.
J. Christo Heunis (13046945)   +3 more
core   +1 more source

Yield of facility-based verbal screening amongst household contacts of patients with multi-drug resistant tuberculosis in Pakistan

open access: yesJournal of Clinical Tuberculosis and Other Mycobacterial Diseases, 2017
Background: Household contacts of multidrug-resistant tuberculosis (MDR-TB) patients are at a high risk of getting infected with TB/MDR-TB, therefore symptomatic or vulnerable individuals should be screened and treated early.
Ejaz Qadeer   +7 more
doaj   +1 more source

Semi‐Mechanistic Joint Population Pharmacokinetic Modeling of the Novel Antituberculosis Drug Sorfequiline and Its Metabolite M3 in Healthy Volunteers

open access: yesCPT: Pharmacometrics &Systems Pharmacology, Volume 15, Issue 9, September 2026.
ABSTRACTSorfequiline is a novel diarylquinoline in development for treatment of tuberculosis. In vitro data suggest metabolism via CYP3A4, carrying the potential for presystemic metabolism and drug–drug interactions. Its major metabolite, M3, is pharmacologically active.
Jose M. Calderin   +5 more
wiley   +1 more source

Multidrug-resistant tuberculosis and risk factors associated with its development: a retrospective study

open access: yesJournal of Infection in Developing Countries, 2015
Introduction: Multidrug-resistant tuberculosis (MDR-TB) has emerged as a major clinical public health threat and challenges the national TB control program in Malaysia. Data that elaborates on the risk factors associated with the development of MDR-TB is
Omar Sald Elmi   +5 more
doaj   +1 more source

Pediatric Tuberculosis in North Kivu: The Urgency of a Targeted Response to a Forgotten Childhood Disease

open access: yesPublic Health Challenges, Volume 5, Issue 3, September 2026.
ABSTRACT Pediatric tuberculosis remains a neglected health emergency, particularly in fragile contexts such as North Kivu province in the Democratic Republic of Congo. While more than one million children contract tuberculosis each year worldwide, the majority of cases remain underdiagnosed, resulting in preventable morbidity and mortality.
Germain Cebweru Murhola   +6 more
wiley   +1 more source

Diagnosis of non-MDR-TB and MDR-TB and the development of acquired (treatment-associated) MDR-TB.

open access: yes, 2012
Diagram showing the detection of non-MDR-TB and MDR-TB. Individuals with MDR-TB transition through a state in which they are treated with standard first-line (DOTS) therapy before the multidrug resistance of their strain is detected.
Dilshod Pulatov (117174)   +8 more
core   +1 more source

Home - About - Disclaimer - Privacy